Dr. Jennifer L. Myers
Claim this profileVirginia Commonwealth University/Massey Cancer Center
Studies Bile Duct Cancer
Studies Cancer
8 reported clinical trials
20 drugs studied
Area of expertise
1Bile Duct Cancer
Stage IV
Stage III
2Cancer
Stage IV
Stage III
LARS
Affiliated Hospitals
Clinical Trials Jennifer L. Myers is currently running
Peposertib + Avelumab + Radiation
for Hepatobiliary Cancer
This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Giving peposertib in combination with avelumab and hypofractionated radiation therapy may work better than other standard chemotherapy, hormonal, targeted, or immunotherapy medicines available in treating patients with solid tumors and hepatobiliary malignancies.
Recruiting1 award Phase 1 & 210 criteria
Atezolizumab + Chemotherapy
for Stomach and Esophageal Cancer
This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel, oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for controlling the growth and/or spreading of the disease in patients with gastric or gastroesophageal junction (JEG) cancer that has not spread from where it first started (local) or only has spread to nearby lymph nodes or tissue (locoregional) and has high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). The mismatch repair (MMR) system in the body corrects errors made during the copying of DNA and serves as a proofreading function. If this system isn't working correctly, mutations (changes) in DNA occur which can allow the cancer to grow or spread. This is called dMMR (deficient mismatch repair) . MSI-H describes cancer cells that have a high number of mutations within microsatellites. For example, microsatellite testing that shows mutations in 30% or more microsatellites is called microsatellite instability-high (MSI-H). Microsatellites are short, repeated sequences of DNA. There is evidence that MSI-H/ dMMR gastric or GEJ tumors respond well to immunotherapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Chemotherapy drugs such as leucovorin calcium and fluorouracil work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using atezolizumab as immunotherapy with and following chemotherapy versus atezolizumab alone prior to and after surgery may shrink or stabilize the tumor in patients with MSI-H/dMMR localized gastric or GEJ cancer and may increase the length of time after treatment that cancer does not come back or get worse.
Recruiting1 award Phase 2
More about Jennifer L. Myers
Clinical Trial Related4 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jennifer L. Myers has experience with
- Nab-paclitaxel
- Cisplatin
- Gemcitabine Hydrochloride
- Atezolizumab
- Peposertib
- Avelumab
Breakdown of trials Jennifer L. Myers has run
Bile Duct Cancer
Cancer
Gallbladder Cancer
Intrahepatic Cholangiocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jennifer L. Myers specialize in?
Jennifer L. Myers focuses on Bile Duct Cancer and Cancer. In particular, much of their work with Bile Duct Cancer has involved Stage IV patients, or patients who are Stage III.
Is Jennifer L. Myers currently recruiting for clinical trials?
Yes, Jennifer L. Myers is currently recruiting for 3 clinical trials in Richmond Virginia. If you're interested in participating, you should apply.
Are there any treatments that Jennifer L. Myers has studied deeply?
Yes, Jennifer L. Myers has studied treatments such as Nab-paclitaxel, Cisplatin, Gemcitabine Hydrochloride.
What is the best way to schedule an appointment with Jennifer L. Myers?
Apply for one of the trials that Jennifer L. Myers is conducting.
What is the office address of Jennifer L. Myers?
The office of Jennifer L. Myers is located at: Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia 23298 United States. This is the address for their practice at the Virginia Commonwealth University/Massey Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.